Genmab A/S logo
Genmab A/S GMAB
$ 27.56 -7.07%

Quarterly report 2022-Q2
added 08-10-2022

report update icon

Genmab A/S Gross Profit 2011-2026 | GMAB

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Genmab A/S

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - - - - - - -182 M

All numbers in DKK currency

Indicator range from annual reports

Maximum Minimum Average
-182 M -182 M -182 M

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
-104 K $ 0.82 -3.48 % $ 4.47 M chinaChina
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
58.4 M $ 33.23 -4.03 % $ 584 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.27 M - 2.71 % $ 14 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-523 K - -11.43 % $ 502 K usaUSA
Athersys Athersys
ATHX
1.44 M - 3.77 % $ 22.4 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
4.77 M - - $ 521 M usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
38.1 M $ 64.66 -1.37 % $ 12.4 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
14 M - -4.8 % $ 255 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
2.32 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Avid Bioservices Avid Bioservices
CDMO
7.32 M - - $ 789 M usaUSA
Certara Certara
CERT
129 M $ 7.16 1.49 % $ 1.15 B usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
1.07 - - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
4.15 M - -16.75 % $ 25.8 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
123 M - -7.23 % $ 13 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
310 $ 25.91 -3.56 % $ 694 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
87.5 M $ 24.0 0.5 % $ 2.93 B usaUSA
Acasti Pharma Acasti Pharma
ACST
-32.3 K - 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
52.8 M $ 0.99 -3.28 % $ 72.7 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
4.2 K - - $ 1.2 B usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
5.88 K - -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
1.94 M - -4.36 % $ 27 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-10.6 M - - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
4.73 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
102 K - -10.17 % $ 12.2 K usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
21.1 M $ 17.54 -3.36 % $ 450 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
-22 K - 7.55 % $ 38.1 M usaUSA